Full Picture

Extension usage examples:

Here's how our browser extension sees the article:
Appears well balanced

Article summary:

1. OVID was a phase 3 trial investigating whether thromboprophylaxis with enoxaparin would prevent untoward hospitalisation and death in symptomatic, but clinically stable outpatients with COVID-19.

2. The 30-day risk of the primary outcome (untoward hospitalisation and all-cause death) was similar in participants allocated to receive enoxaparin and in controls.

3. No major bleeding events were recorded, and no deaths were reported during the study.

Article analysis:

The article is generally reliable and trustworthy, as it is based on a randomized, open-label, parallel-group, investigator-initiated, phase 3 trial conducted at eight centres in Switzerland and Germany. The study was registered in ClinicalTrials.gov (NCT04400799), which adds to its credibility. Furthermore, the authors have provided detailed information about the methods used for the study as well as the results obtained from it.

The article does not appear to be biased or one-sided; rather, it presents both sides of the argument equally by providing evidence for both the efficacy of enoxaparin for thromboprophylaxis in COVID-19 patients as well as its lack thereof. Additionally, potential risks associated with using enoxaparin are noted throughout the article.

The only potential issue with this article is that it does not explore any counterarguments or alternative treatments that could be used instead of enoxaparin for thromboprophylaxis in COVID-19 patients. However, this does not detract from its overall reliability or trustworthiness since this is beyond the scope of this particular study.